CTI BIOPHARMA CORP Form 8-K December 11, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2014 (December 5, 2014)

CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

Washington001-1246591-1533912(State or other jurisdiction of(Commission(I.R.S. Employer

incorporation or organization) File Number) Identification Number) 3101 Western Avenue, Suite 600

Seattle, Washington 98121

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

Not applicable

Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

(Former name or former address, if changed since last report).

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

As CTI BioPharma Corp. previously disclosed in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014 filed with the Securities and Exchange Commission on October 31, 2014, the director defendants in the matter Lopez & Gilbert v. Nudelman, et al., Case No. 14-2-18941-9 SEA, had moved to dismiss the complaint in the matter in September 2014. On December 5, 2014, the court determined not to grant such motion. The trial date is currently set for August 24, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: December 11, 2014 By: /s/ Louis A. Bianco Louis A. Bianco Executive Vice President, Finance and Administration